FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba biotech

"- Ambitious development program for multiple solid tumors with high unmet need, starting with low grade upper tract urothelial cancer (UTUC) - Follows successful clearance of the IND application in Dec 2020 allowing initiation of pivotal Phase 3 clinical trial in patients with low grade UTUC; results to form basis of application for FDA approval."

111621 FDA Grants Fast Track Designation
.
Download • 90KB



Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC